Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

Home

/

LQDA

L

Liquidia Corporation (LQDA)

NCM – Real vaqt narxi. Valyuta: USD

56.60

+3.47 (6.53%)

Yopilishda: May 12, 2026, 4:00 PM EDT

56.31

-0.29 (-0.51%)

Bozordan keyin: May 12, 2026, 7:53 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

These Analysts Boost Their Forecasts On Liquidia After Upbeat Q1 Results

These Analysts Boost Their Forecasts On Liquidia After Upbeat Q1 Results

Liquidia Corp (NASDAQ:LQDA) on Monday reported better-than-expected first-quarter financial results.

Liquidia: Yutrepia's Launch Momentum Is Approaching A Ceiling (Rating Downgrade)

Liquidia: Yutrepia's Launch Momentum Is Approaching A Ceiling (Rating Downgrade)

Liquidia delivered strong Q1 results, with Yutrepia net sales up 44% sequentially and a third consecutive profitable quarter. LQDA now commands a 23% share of the inhaled prostacyclin segment, but further market share gains are likely capped by entrenched competitors and limited product differentiation. At a near $5 billion market cap and 9x run-rate revenue, the current valuation assumes sustained momentum and peak Yutrepia sales north of $1.2 billion, which appears optimistic.

Why This Biotech Stock Just Broke Out To A Record High

Why This Biotech Stock Just Broke Out To A Record High

Liquidia stock broke out to a record high Monday after the company smashed first-quarter sales expectations.

Liquidia Corporation (LQDA) Q1 2026 Earnings Call Transcript

Liquidia Corporation (LQDA) Q1 2026 Earnings Call Transcript

Liquidia Corporation (LQDA) Q1 2026 Earnings Call Transcript

Liquidia Q1 Earnings Call Highlights

Liquidia Q1 Earnings Call Highlights

Liquidia NASDAQ: LQDA reported sharply higher first-quarter 2026 sales and profitability as executives said the launch of YUTREPIA continued to gain traction in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

Liquidia Corporation (LQDA) Surpasses Q1 Earnings and Revenue Estimates

Liquidia Corporation (LQDA) Surpasses Q1 Earnings and Revenue Estimates

Liquidia Corporation (LQDA) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to a loss of $0.45 per share a year ago.

Liquidia Corporation Reports First Quarter 2026 Financial Results

Liquidia Corporation Reports First Quarter 2026 Financial Results

YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $130 million in the first quarter of 2026 More than 4,500 unique patient prescriptions and approximately 3,750 patients treated between launch in June 2025 and April 30, 2026 Recorded third consecutive quarter of profitability, with net income of approximately $53 million, adjusted EBITDA of $71 million and an increase in cash and cash equivalents by $32 million compared to the fourth quarter of 2025 Actively screening PH-ILD patients in Phase 4 Tyvaso® and Tyvaso DPI® transition study and pivotal Phase 3 Re-Spire study of L606 MORRISVILLE, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the first quarter ended March 31, 2026.

Videolar

No Data

There is no data to display

Press-relizlar

Liquidia Corporation Reports First Quarter 2026 Financial Results

Liquidia Corporation Reports First Quarter 2026 Financial Results

YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $130 million in the first quarter of 2026 More than 4,500 unique patient prescriptions and approximately 3,750 patients treated between launch in June 2025 and April 30, 2026 Recorded third consecutive quarter of profitability, with net income of approximately $53 million, adjusted EBITDA of $71 million and an increase in cash and cash equivalents by $32 million compared to the fourth quarter of 2025 Actively screening PH-ILD patients in Phase 4 Tyvaso® and Tyvaso DPI® transition study and pivotal Phase 3 Re-Spire study of L606 MORRISVILLE, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the first quarter ended March 31, 2026.

Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

MORRISVILLE, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the full year ended December 31, 2025. The company will also host a webcast at 8:30 a.m. ET on March 5, 2026, to discuss its financial results and provide a corporate update.

Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update

MORRISVILLE, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, today announced its financial results for the second quarter ended June 30, 2025. The company will also host a webcast at 8:30 a.m. Eastern Time on August 12, 2025, to review financial performance and provide a corporate update.